Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20608618 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL809615 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL6897539 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL6902252 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL812763 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL6902742 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL6897541 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL812328 | 1.00 | PRKCA (0.42) | PRKCATSHRCCR6PPARGALOX5 | |
| SCHEMBL440372 | 0.98 | PRKCA (0.40) | PRKCATSHRCCR6NFKB1NFKB2 | |
| SCHEMBL20608590 | 0.98 | PRKCA (0.40) | PRKCATSHRCCR6NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-11701305-B2 | Unit dose sachet comprising a perfume gel composition | Spritz, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4104815-A1 | UNIT DOSE SACHET COMPRISING A PERFUME GEL COMPOSITION | Spr1tz, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395434-A1 | UNIT DOSE SACHET COMPRISING A PERFUME GEL COMPOSITION | SPR1TZ INC. | 2022-12-15 | — | — | US | disclosed |
| CN-110891615-B | System and method for selecting and releasing fragrance | 阿甘香气及精细化学有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-106999972-A | System and method for discharging fragrance | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-6833481-B2 | Catalytic dehydrative isomerization | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1316541-A1 | Process for producing 2-alkyl-2-cyclopentenones | Takasago International Corporation (JP) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | PRKCA 3705/4885TSHR 414/4885CCR6 527/4885 |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | HSD3B2, DHPS, HSD3B1 | PRKCA 1600/4885TSHR 332/4885CCR6 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.